AASK AND HYPERTENSION COHORT STUDY

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心机构，不一定为研究者机构。非裔美国人有患高血压的严重后果的危险。尽管血压控制良好，尽管使用肾脏保护性降压药物，高血压相关肾脏疾病通常进展。非裔美国人肾病和高血压研究（AASK）是一项长期、多中心、前瞻性、随机、双盲试验，旨在确定血压控制水平和使用特异性抗高血压方案对非裔美国人高血压肾硬化患者肾功能不全进展的影响。AASK是同类研究中的第一个大规模研究，该研究的干预部分最近成功完成。AASK研究表明，即使在接受最有效治疗的组中，非裔美国人受试者的临床终点发生率和肾脏疾病进展也很高。 因此，AASK队列研究旨在前瞻性地确定患有高血压相关肾脏疾病的非裔美国人的肾功能长期病程和肾脏疾病进展的风险因素，这些疾病提供了控制血压的最佳治疗。 队列研究的次要目的是确定心血管疾病的发生率，并评估其在高血压相关肾脏疾病背景下的风险因素。预计AASK队列研究将提供数据，增强对决定肾脏疾病进展的过程的理解。这项研究的成功完成可能最终导致新的预防策略，延迟终末期肾病的发作。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. African American are at risk to suffer severe consequences of hypertension. Despite excellent blood pressure control and despite use of reno-protective antihypertensive medication, hypertension-related renal disease commonly progresses. The African American Study of Kidney Disease and Hypertension (AASK) was a long-term multi-center, prospective, randomized double0blinded trial to determine the effects of blood pressure control levels and the use of specific anti-hypertensive regimens on the progression of renal insufficiency in African Americans with hypertensive nephrosclerosis. The AASK was the first large-scale study of its kind, and the intervention part of the study was recently and successfully completed. The AASK study demonstrated that the incidence of clinical endpoints and the progression of kidney disease were high in the African American subjects, even in the group that received the most effective therapy. Therefore, the AASK Cohort study is designed to determine prospectively the long-term course of kidney function and risk factors for kidney disease progression in African Americans with hypertension-related kidney disease that are provided optimal therapy to control blood pressure. A secondary objective of the Cohort study is to determine the occurance of cardiovascular disease and assess its risk factors in the setting of hypertension-related kidney disease. It is anticipated that the AASK Cohort study will provide data that enhance the understanding of the processes that determine progression of renal disease. Successful completion of this study might ultimately lead to new prevention strategies that delay the onset of end Stage renal disease.